scispace - formally typeset
S

Shuwen Liu

Researcher at Southern Medical University

Publications -  416
Citations -  21324

Shuwen Liu is an academic researcher from Southern Medical University. The author has contributed to research in topics: Craton & Medicine. The author has an hindex of 51, co-authored 367 publications receiving 16630 citations. Previous affiliations of Shuwen Liu include New York Blood Center & South China University of Technology.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.

Yuan Huang, +4 more
- 01 Sep 2020 - 
TL;DR: Recent research advance in the structure, function and development of antivirus drugs targeting the spike (S) protein of SARS-CoV-2 is highlighted.
Journal ArticleDOI

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Lanying Du, +5 more
- 09 Feb 2009 - 
TL;DR: Recent advances in the development of vaccines and therapeutics based on the S protein are highlighted, which plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.
Journal ArticleDOI

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.

Shuai Xia, +16 more
- 30 Mar 2020 - 
TL;DR: EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively.
Journal ArticleDOI

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.

Shuai Xia, +11 more
- 11 Feb 2020 - 
TL;DR: A novel coronavirus, 2019-nCoV, emerged in Wuhan, China and then quickly spread worldwide, resulting in >17,388 confirmed cases and 361 deaths as of 3 February 2020, thus calling for the development of safe and effective therapeutics and prophylatics.